Last reviewed 2026-04-23 · How we verify

Low Dose RBT-1

Renibus Therapeutics, Inc. · Phase 2 active Small molecule

Low Dose RBT-1 is a Renin-angiotensin system inhibitor Small molecule drug developed by Renibus Therapeutics, Inc.. It is currently in Phase 2 development for Hypertension, Heart failure.

Low Dose RBT-1 is a renin-angiotensin system inhibitor.

Low Dose RBT-1 is a renin-angiotensin system inhibitor. Used for Hypertension, Heart failure.

Likelihood of approval

13.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Cardiovascular Phase 3 risk -2.0pp
Modern cardiovascular outcome trials are large + long; many fail to beat aggressive standard-of-care.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Low Dose RBT-1
Sponsor	Renibus Therapeutics, Inc.
Drug class	Renin-angiotensin system inhibitor
Target	Angiotensin II receptor
Modality	Small molecule
Therapeutic area	Cardiovascular
Phase	Phase 2

Mechanism of action

It works by blocking the action of angiotensin II, a potent vasoconstrictor, which leads to vasodilation and decreased blood pressure. This results in reduced strain on the heart and kidneys, making it an effective treatment for hypertension and heart failure.

Approved indications

Hypertension
Heart failure

Common side effects

Cough
Dizziness
Headache

Key clinical trials

Effect of RBT-1 on Preconditioning Response Biomarkers in Subjects Undergoing CABG and/or Cardiac Valve Surgery (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Low Dose RBT-1 CI brief — competitive landscape report
Low Dose RBT-1 updates RSS · CI watch RSS
Renibus Therapeutics, Inc. portfolio CI

Frequently asked questions about Low Dose RBT-1

What is Low Dose RBT-1?

Low Dose RBT-1 is a Renin-angiotensin system inhibitor drug developed by Renibus Therapeutics, Inc., indicated for Hypertension, Heart failure.

How does Low Dose RBT-1 work?

Low Dose RBT-1 is a renin-angiotensin system inhibitor.

What is Low Dose RBT-1 used for?

Low Dose RBT-1 is indicated for Hypertension, Heart failure.

Who makes Low Dose RBT-1?

Low Dose RBT-1 is developed by Renibus Therapeutics, Inc. (see full Renibus Therapeutics, Inc. pipeline at /company/renibus-therapeutics-inc).

What drug class is Low Dose RBT-1 in?

Low Dose RBT-1 belongs to the Renin-angiotensin system inhibitor class. See all Renin-angiotensin system inhibitor drugs at /class/renin-angiotensin-system-inhibitor.

What development phase is Low Dose RBT-1 in?

Low Dose RBT-1 is in Phase 2.

What are the side effects of Low Dose RBT-1?

Common side effects of Low Dose RBT-1 include Cough, Dizziness, Headache.

What does Low Dose RBT-1 target?

Low Dose RBT-1 targets Angiotensin II receptor and is a Renin-angiotensin system inhibitor.

Drug class: All Renin-angiotensin system inhibitor drugs
Target: All drugs targeting Angiotensin II receptor
Manufacturer: Renibus Therapeutics, Inc. — full pipeline
Therapeutic area: All drugs in Cardiovascular
Indication: Drugs for Hypertension
Indication: Drugs for Heart failure

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing